eli lilly glp 1 analog launches GLP-1 pill, kicking off showdown with Novo Nordisk Eli Lilly announces successful trial

In the 2026 ADA Scientific Sessions, results from the Phase-3 TRANSCEND-T2D-1 study involving retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, showed up to a 2% decrease in A1C and a 16.8% decrease in body weight over 40 weeks in patients with type 2 diabetes

Is telehealth peptide therapy available

Peptides help with chronic inflammation by calming inflammatory signals at their source, supporting tissue repair, and working alongside your body's natural healing processes rather than broadly suppressing them

H., Cognard, E

published dosage figures refer to experimental animal/in-vitro studies, not human protocols